0219

Welcome to the February issue! The elderly are the central focus of our cover feature as we ask how pharma can better meet the diverse needs of older patients. Meanwhile in Upfront, we present an infographic snapshot of drug development in Europe, and researchers also enlighten us about the therapeutic potential of nanoparticles. In Business, George Chressanthis argues that the CVS-Aetna merger will prove a transformative event for pharma, while James Strachan explores the consequences of a “no-deal” Brexit for the drug development industry. We also Sit Down With Steve Arlington, who is facilitating collaborations as President at the Pistoia Alliance.

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

I want to receive an alert when the next issue is available online

Articles featured in this issue

Business & Regulation Trends & Forecasts

Ask, and Ye Shall Receive

02/25/2019 | James Strachan

Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.

Manufacture Technology and Equipment

Who's the Best?

02/19/2019 | Stephanie Vine

Vote now for the top drug development technology of 2018.

Discovery & Development Small Molecules

Remembering Stewart Adams OBE

02/13/2019 | Stephanie Vine

The inventor of ibuprofen died on January 30, aged 95.

Discovery & Development Drug Discovery

When Noses Counterattack

01/22/2019 | Maryam Mahdi

Mimicking the exomes secreted by nasal cells in response to bacteria could boost drug uptake

Discovery & Development Drug Discovery

Tiny Dancers

01/22/2019 | Maryam Mahdi

Could observation of waltzing therapeutic nanoparticles help determine drug efficacy?

Business & Regulation Trends & Forecasts

Medicine Making in Europe

02/14/2019 | Stephanie Vine

EFPIA figures give a snapshot of drug development and innovation in Europe. Check out our infographic for some of the key stats.

Discovery & Development Small Molecules

Solutions in... Drug Development

02/19/2019 | James Strachan

Douglas J. Swirsky, CEO of Rexahn Pharmaceuticals, explains his company’s approach to developing more effective cancer treatments.

Manufacture Contract Manufacturing Services

Phasing Out Inefficiency

02/21/2019 | Simon Tyler

Struggling with process research and development? Find yourself a CRO that knows what it’s doing.

Discovery & Development Formulation

Taste the Rainbow

02/20/2019 | Nicolas Madit

The color of a capsule or tablet can have a big impact on compliance and branding. To avoid delays, early decisions have to be made.

Discovery & Development Clinical Trials

With Age Comes Challenges But Not Trials

02/27/2019 | Maryam Mahdi, Stephanie Vine

A key focus of Andrew McLachlan’s career is understanding the impact of aging on drug disposition and response to medicines.

Manufacture Packaging

Packaging for All

03/08/2019 | Stephen Wilkins

When considering the elderly, we can’t stop at drug development – packaging needs special consideration too.

Discovery & Development Formulation

Owner of a Lonely Heart

02/18/2019 | Jessica Finlay

In 2018, the UK’s government appointed its first Minister for Loneliness. The role: to tackle loneliness.

Business & Regulation Trends & Forecasts

Mergers and Big Decisions

02/18/2019 | George Chressanthis, Randy Risser

Why the CVS-Aetna merger could be a transformative event for the pharmaceutical industry.

Business & Regulation Business Practice

Facing the Brexit Trial

02/12/2019 | James Strachan

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.